HC Wainwright Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. Needham & Company LLC cut their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $2.41 on Tuesday. The firm’s 50-day moving average price is $1.99 and its 200-day moving average price is $2.14. Esperion Therapeutics has a 52-week low of $1.15 and a 52-week high of $3.40. The company has a market cap of $474.87 million, a PE ratio of -3.63 and a beta of 0.96.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors have recently bought and sold shares of ESPR. Barclays PLC grew its holdings in Esperion Therapeutics by 99.6% during the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 154,509 shares during the period. Geode Capital Management LLC lifted its position in shares of Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $606,000. Anson Funds Management LP purchased a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $540,000. Finally, Wellington Management Group LLP raised its stake in Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after acquiring an additional 241,512 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.